Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 10/20 | 0.50 |
| ▸ | P2RX2 | Q9UBL9 | 10/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5854429 | 1.00 | P2RX3 (0.50) | P2RX3P2RX2GAAGRM2TP53 | |
| SCHEMBL5853254 | 0.86 | P2RX3 (0.53) | P2RX3P2RX2GAAIDH1 | |
| SCHEMBL5853264 | 0.86 | P2RX3 (0.53) | P2RX3P2RX2GAAIDH1 | |
| SCHEMBL5855065 | 0.77 | PIK3CA (0.47) | GAAGRM2IDH1 | |
| SCHEMBL5855070 | 0.77 | PIK3CA (0.47) | GAAGRM2IDH1 | |
| SCHEMBL1936824 | 0.77 | IDH1 (0.44) | P2RX3P2RX2IDH1 | |
| SCHEMBL28627879 | 0.74 | LMNA (0.42) | TP53IDH1 | |
| SCHEMBL2366383 | 0.73 | P2RX3 (0.48) | P2RX3P2RX2IDH1 | |
| SCHEMBL2366332 | 0.73 | P2RX3 (0.48) | P2RX3P2RX2IDH1 | |
| SCHEMBL2366328 | 0.73 | P2RX3 (0.48) | P2RX3P2RX2IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992103-B2 | Benzamide derivatives, processes for their preparation, and their pharmaceutical use | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-01-31 | — | — | US | disclosed |
| US-20050085520-A1 | Benzamide derivatives, processes for their preparation, and their pharmaceutical use | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-04-21 | — | — | US | disclosed |
| EP-1448520-A1 | BENZAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003045913-A1 | BENZAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085520-A1 | Benzamide derivatives, processes for their preparation, and their pharmaceutical use | BACE2, PSEN2, BACE1 | P2RX3 2716/4885P2RX2 1574/4885GAA 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.